Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 3 of this Exclusive Interview, Dr. Taub discusses the possible negative effects of PCSK9 Inhibitors. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on general and preventive cardiology. …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 4 of this Exclusive Interview, Dr. Taub explains when and how she continues to work with diabetes patients versus referring them to a specialist. Dr. Pam R. Taub, MD, FACC is a …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 5 of this Exclusive Interview, Dr. Taub explains her effective methods of treating the patient that may benefit other medical professionals. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 6 of this Exclusive Interview, Dr. Taub discusses calcium scores and starting patients on PCSK9. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on general and preventive cardiology. …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 7 of this Exclusive Interview, Dr. Taub explains her comfort level with the newest drugs. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on general and preventive cardiology. …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 8, the conclusion of this Exclusive Interview, Dr. Taub shares her findings after using new medications with her patients. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on …

We have had many articles that look at why certain people develop insulin resistance more easily than others. There are many different theories as to why this resistance occurs, but in every case no one has offered a real solution to this problem. In our second special report on the …

As concluded in the previous newsletter in this series, “Evolutionary selection for insulin resistance in a cyclic environment: brain clocks and control of peripheral metabolism” the brain is equipped with circadian neurophysiological mechanisms to induce (and reverse) the insulin resistant state that evolved as a survival strategy against ensuing environmental stresses such as prolonged (seasonal) lack of food availability. A central facilitator of this insulin resistance induction is a diminution of the circadian peak in dopaminergic activity at the SCN. Neurotoxin induced destruction of these dopaminergic projections to the clock of insulin sensitive animals induces marked insulin resistance and glucose intolerance without alterations in food consumption.

Given the potential for CVD risk reduction associated with metformin and B-QR therapy individually, the present study explored the effect of add-on B-QR vs placebo to metformin on CVD outcomes in T2DM subjects.

Five or six years ago, the widespread advertising of $4 dollar drug programs was in the wheelhouse of every pharmacy, and there were hundreds of drugs on the list. Since then the list has gotten much shorter and the number of pharmacies advertising them has decreased. Part of the reason …